Stabilisation of PRCP by deubiquitinase-targeting chimera (DUBTAC) to replenish autophagy for ameliorating pathological cardiac hypertrophy.

IF 6.8 2区 医学 Q1 PHARMACOLOGY & PHARMACY
Fangchao Zhou, Jun Xia, Yingjuan Liu, Wenqi He, Hongyuan Zhang, Bernard D Keavney, Min Zi, Binh Y Nguyen, Tamer M A Mohamed, Jessica M Miller, Riham R E Abouleisa, Susanne S Hille, Elizabeth J Cartwright, Oliver J Müller, Honglin Xu, Sam Butterworth, Xin Wang
{"title":"Stabilisation of PRCP by deubiquitinase-targeting chimera (DUBTAC) to replenish autophagy for ameliorating pathological cardiac hypertrophy.","authors":"Fangchao Zhou, Jun Xia, Yingjuan Liu, Wenqi He, Hongyuan Zhang, Bernard D Keavney, Min Zi, Binh Y Nguyen, Tamer M A Mohamed, Jessica M Miller, Riham R E Abouleisa, Susanne S Hille, Elizabeth J Cartwright, Oliver J Müller, Honglin Xu, Sam Butterworth, Xin Wang","doi":"10.1111/bph.70094","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and purpose: </strong>Autophagy is essential for cellular homeostasis, and its impairment contributes to cardiac hypertrophy. Modulating autophagy has shown potential in treating pathological hypertrophy. Prolylcarboxypeptidase (PRCP), a lysosomal enzyme that hydrolyzes angiotensin II to Ang1-7, has an unclear role in cardiac autophagy and hypertrophy. This study explores PRCP's function in regulating autophagy under hypertrophic stress and its potential as a therapeutic target.</p><p><strong>Experimental approach: </strong>Transverse aortic constriction (TAC) was used to induce hypertrophy in mice. PRCP-knockout (PRCP<sup>KO</sup>) mice were generated using CRISPR/Cas9, while PRCP was overexpressed in the heart using adeno-associated virus 9. Cardiac function was evaluated via echocardiography and histological analysis. Autophagy markers were assessed by immunostaining, electron microscopy, and protein expression. In vitro, PRCP expression was manipulated in H9c2 cells. A novel DUBTAC compound was also synthesized to stabilize PRCP, and its protective effects were tested in H9c2 cells and hESC-derived cardiomyocytes under isoprenaline-induced stress.</p><p><strong>Key results: </strong>PRCP<sup>KO</sup> mice developed more severe cardiac hypertrophy, fibrosis, and diastolic dysfunction after TAC. These mice showed reduced autophagosome formation and decreased expression of autophagy-related proteins WDR1 and WIPI1. In contrast, PRCP overexpression mitigated hypertrophy and preserved autophagy. Mechanistically, PRCP regulated autophagy via the interaction of WDR1 with WIPI1. Stabilizing PRCP with DUBTAC prevented its degradation and maintained autophagy under hypertrophic conditions.</p><p><strong>Conclusions and implications: </strong>PRCP is a previously unrecognized regulator of autophagy in the heart. Enhancing PRCP expression or stabilizing it pharmacologically via DUBTAC represents a novel and effective therapeutic approach for managing pathological cardiac hypertrophy and improving cardiac health.</p>","PeriodicalId":9262,"journal":{"name":"British Journal of Pharmacology","volume":" ","pages":""},"PeriodicalIF":6.8000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/bph.70094","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background and purpose: Autophagy is essential for cellular homeostasis, and its impairment contributes to cardiac hypertrophy. Modulating autophagy has shown potential in treating pathological hypertrophy. Prolylcarboxypeptidase (PRCP), a lysosomal enzyme that hydrolyzes angiotensin II to Ang1-7, has an unclear role in cardiac autophagy and hypertrophy. This study explores PRCP's function in regulating autophagy under hypertrophic stress and its potential as a therapeutic target.

Experimental approach: Transverse aortic constriction (TAC) was used to induce hypertrophy in mice. PRCP-knockout (PRCPKO) mice were generated using CRISPR/Cas9, while PRCP was overexpressed in the heart using adeno-associated virus 9. Cardiac function was evaluated via echocardiography and histological analysis. Autophagy markers were assessed by immunostaining, electron microscopy, and protein expression. In vitro, PRCP expression was manipulated in H9c2 cells. A novel DUBTAC compound was also synthesized to stabilize PRCP, and its protective effects were tested in H9c2 cells and hESC-derived cardiomyocytes under isoprenaline-induced stress.

Key results: PRCPKO mice developed more severe cardiac hypertrophy, fibrosis, and diastolic dysfunction after TAC. These mice showed reduced autophagosome formation and decreased expression of autophagy-related proteins WDR1 and WIPI1. In contrast, PRCP overexpression mitigated hypertrophy and preserved autophagy. Mechanistically, PRCP regulated autophagy via the interaction of WDR1 with WIPI1. Stabilizing PRCP with DUBTAC prevented its degradation and maintained autophagy under hypertrophic conditions.

Conclusions and implications: PRCP is a previously unrecognized regulator of autophagy in the heart. Enhancing PRCP expression or stabilizing it pharmacologically via DUBTAC represents a novel and effective therapeutic approach for managing pathological cardiac hypertrophy and improving cardiac health.

用去泛素酶靶向嵌合体(DUBTAC)补充自噬来稳定PRCP以改善病理性心肌肥大。
背景与目的:细胞自噬是维持细胞内稳态所必需的,自噬损伤可导致心肌肥厚。调节自噬已显示出治疗病理性肥大的潜力。脯氨酸羧肽酶(PRCP)是一种溶酶体酶,可将血管紧张素II水解为Ang1-7,在心脏自噬和肥大中作用尚不清楚。本研究探讨了PRCP在肥厚应激下调节自噬的功能及其作为治疗靶点的潜力。实验方法:采用主动脉横缩法(TAC)诱导小鼠心肌肥厚。使用CRISPR/Cas9技术生成PRCP敲除(PRCPKO)小鼠,而使用腺相关病毒9在心脏中过表达PRCP。通过超声心动图和组织学分析评估心功能。通过免疫染色、电镜和蛋白表达评估自噬标志物。体外,在H9c2细胞中调控PRCP的表达。我们还合成了一种新的DUBTAC化合物来稳定PRCP,并在异丙肾上腺素诱导应激的H9c2细胞和hesc来源的心肌细胞中测试了其保护作用。关键结果:PRCPKO小鼠在TAC后出现更严重的心脏肥厚、纤维化和舒张功能障碍。这些小鼠显示自噬体形成减少,自噬相关蛋白WDR1和WIPI1的表达减少。相比之下,PRCP过表达减轻了肥大并保留了自噬。在机制上,PRCP通过WDR1与WIPI1的相互作用调节自噬。在肥厚条件下,DUBTAC稳定PRCP可防止其降解并维持自噬。结论和意义:PRCP是一种以前未被认识的心脏自噬调节因子。通过DUBTAC增强PRCP表达或从药理学上稳定其表达是一种新的有效的治疗方法,可用于控制病理性心肌肥厚和改善心脏健康。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
15.40
自引率
12.30%
发文量
270
审稿时长
2.0 months
期刊介绍: The British Journal of Pharmacology (BJP) is a biomedical science journal offering comprehensive international coverage of experimental and translational pharmacology. It publishes original research, authoritative reviews, mini reviews, systematic reviews, meta-analyses, databases, letters to the Editor, and commentaries. Review articles, databases, systematic reviews, and meta-analyses are typically commissioned, but unsolicited contributions are also considered, either as standalone papers or part of themed issues. In addition to basic science research, BJP features translational pharmacology research, including proof-of-concept and early mechanistic studies in humans. While it generally does not publish first-in-man phase I studies or phase IIb, III, or IV studies, exceptions may be made under certain circumstances, particularly if results are combined with preclinical studies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信